Autolus Therapeutics reported $74.3 million in 2025 revenue during its first commercial year, while facing a -265% gross margin. The company aims to achieve positive margins by 2026 through scaling production and expanding into autoimmune diseases with promising early lupus trial results. The broader CAR-T therapy market is projected to reach $9.85 billion in the US by 2033.
A study of 366 patients found ide-cel CAR-T cell therapy achieved 81.6% overall response rate in patients 70 or older with relapsed/refractory multiple myeloma, with median progression-free survival of 18.9 months versus 5.7 months with standard regimens.
Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.
CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.
Retrospective analysis of the ZUMA-2 trial found that previous ibrutinib exposure was associated with improved progression-free survival after brexucabtagene autoleucel treatment in mantle cell lymphoma patients, though with increased toxicity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07403812 |
Assessing DCog Short for Neurotoxicity in CAR-T |
NOT_YET_RECRUITING | NA |
| NCT07333976 |
o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer |
COMPLETED | PHASE2 |
| NCT06144151 |
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity |
RECRUITING | |
| NCT06021262 |
Assessment of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity |
UNKNOWN | |
| NCT05950386 |
Effects of Lead Exposure on Ferroptosis Pathway |
UNKNOWN | |
| NCT05798884 |
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients |
UNKNOWN | NA |
| NCT05510596 |
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome |
COMPLETED | NA |
| NCT05094154 |
Effect of Antibiotic Choice On ReNal Outcomes (ACORN) |
COMPLETED | PHASE4 |
| NCT05089604 |
Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations |
RECRUITING | PHASE4 |
| NCT05040230 |
EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language |
COMPLETED |
